AntriaBio Completes Merger With Nevada Corporation

The new company will focus on developing treatment for diabetes patients.

AntriaBio Delaware, Inc. f/k/a AntriaBio, Inc. ("AntriaBio Delaware"), a biopharmaceutical company developing novel therapeutics for the diabetes market, is pleased to announce the closing of its planned and previously announced merger with AntriaBio, Inc. f/k/a Fits My Style Inc., a Nevada corporation. Following the merger, the company is now listed as AntriaBio, Inc. ("AntriaBio"), and trading on the OTC Bulletin Board and the OTCQB under the symbol "FMYY." In connection with the merger, AntriaBio appointed three new directors.

No votes yet

Janssen Research and Development Submits New Diabetes Treatment

The new drug application submitted to the FDA is a fixed-dose combination therapy for patients with Type 2 diabetes.

Janssen Research & Development, LLC  today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a fixed-dose therapy combining canagliflozin and immediate release metformin to treat patients with type 2 diabetes.

No votes yet

BD Launches Advanced Device for Insulin Injection

The Ultra-Fine Nano 4mm pen needles include five-bevel needle tips designed to provide diabetes patients with easier insulin injection.

Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to give themselves insulin injections for reasons that include needle anxiety. Patients who reported injection-related pain or embarrassment also admitted they intentionally skipped insulin injections more often. A study by the American Association of Diabetes Educators (AADE) revealed that 47% of people with diabetes would be more likely to administer their injections regularly if a product were available that would ease the pain and discomfort of injections.

Your rating: None Average: 5 (1 vote)

Aetna Launches Diabetes Management Programs in Texas

The programs are designed to help doctors use drugs, packaging and treatment programs to more effectively find and reach patients living with diabetes.

More than 1.7 million adults in Texas are living with diabetes. Research shows this is 12 percent higher than the national average. Doctors here say their biggest challenge is knowing which patients are getting the right tests and following their doctors’ treatment orders. To help, Aetna (NYSE: AET) is testing two new programs that give doctors an edge in finding and treating patients with diabetes.

No votes yet

Teva Launches Generic Glucose Control Tablets in U.S.

The company is introducing a generic version of Actos tablets, used to control blood sugar in patients with Type 2 diabetes.

Teva Pharmaceutical Industries announced the launch of an authorized generic of Actos (pioglitazone-hydrochloride tablets) 15, 30 and 45mg. Actos is marketed by Takeda Pharmaceuticals U.S.A., Inc., and used with diet and exercise for blood sugar control in adults with type 2 diabetes.

The brand product had annual sales of approximately $2.7 billion in the United States, based on IMS sales data as of June 30.

No votes yet

Study: Patients Struggle to Control Multiple Chronic Conditions

Research by Kaiser Permanente shows that people with diabetes, high blood pressure, and high cholesterol have difficultly managing the conditions.

Most people who have diabetes, high blood pressure, and high cholesterol have difficultly managing all three conditions; indeed, success is fleeting for those who do manage all three, according to a Kaiser Permanente Institute for Health Research study that appears online in the American Heart Association journal Circulation: Cardiovascular Quality and Outcomes.

No votes yet

Bio-Solutions to Produce Glucose-Control Dietary Supplement

Type2 Defense is a powdered product designed to help diabetic and pre-diabetic patients manage their glucose levels.

Bio-Solutions Corp is pleased to announce that the company has started production of the recently acquired Type2 Defense. Type2 Defense is an Antioxidant and glucose control dietary supplement powder. This proprietary formula is packaged with 30 packets to a box. The product powder drink mix delivery system has been developed to support healthy glucose levels for type 2 diabetics and pre-diabetics.

No votes yet

Echo Therapeutics Announces Needle-free Glucose Monitoring System

The company has patented its Symphony tCGM glucose monitoring system, and the Prelude SkinPrep transdermal drug delivery product.

Echo Therapeutics Inc., a company developing its needle-free Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude SkinPrep System for transdermal drug delivery, today announced the receipt of a notice of allowance for a patent application covering its Prelude SkinPrep System and a notice of issuance for a patent covering its Symphony tCGM System.

No votes yet

Merck, American College of Endocrinology Partner on Blood Sugar Basics Game Plan

The program, featuring promotional support from football personalities, is designed to inform diabetes patients about their treatment options and help manage the disease.

The Blood Sugar Basics Game Plan, developed by the American College of Endocrinology (ACE), with support from Merck (NYSE:MRK) (known as MSD outside the United States and Canada), is kicking off to help the nearly 26 million people in the U.S. who have diabetes find new ways to help manage their disease. The interactive, user-friendly program breaks down diabetes management into four easy-to-understand "goals" to help people with type 2 diabetes take small steps toward better management of their disease.

No votes yet

Report: Record Number of Diabetes Clinical Trials in the Pipeline

Research firm Profil Institute reports burgeoning demand for clinical drug trials.

Profil Institute for Clinical Research, Inc., a company focused on early phase clinical trials for diabetes and obesity, announced today record growth in the number of clinical trials in the pipeline.  Profil Institute also reports an increase in the number of mid-size biotech and off-shore clients, while maintaining active collaborations with the largest global pharmaceutical companies, driven by a strong demand for Phase I and metabolic disease specialization. 

No votes yet
Syndicate content